Search results for Regeneron

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

<![CDATA[Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals ]]>

Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab...

<![CDATA[Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free]]>

A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage

Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.

Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy

Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate that could have better luck bin...

Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collaboration

Regeneron will marry its antibody capabilities with Parabilis’ stabilized helical peptide or Helicon™ platform, with the goal of developing both Antibody-Helicon™ Conjugates...

White House announces MFN agreement with drug manufacturer Regeneron

The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is the 17th such agreem...

Biocon Files PGR Petition Challenging Regeneron Eylea® Patent and Seeks Joinder with Alvotech Proceeding

On April 2, 2026, Biocon filed a petition for post-grant review (“PGR”) challenging Regeneron’s U.S. Patent No. 12,168,036 (“the ’036 patent”), which is directed to methods for tre...

Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix

With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals.

Parabilis Files for IPO, a Day After Signing Up-to-$2.3B Regeneron Collaboration

The company’s IPO filing came a day after Parabilis inked an up-to-$2.3 billion-plus strategic research collaboration with Regeneron Pharmaceuticals to discover and develop an init...

Coultreon banks $125M to support testing of former Galapagos immune drug

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological dise...

Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?

Regeneron Gets Landmark FDA Approval for First Gene Therapy for Hearing Loss

Regeneron Pharmaceuticals’ Otarmeni is now approved for treating hearing loss from an ultra-rare genetic mutation found in an estimated 50 newborns per year. While Regeneron will o...

Regeneron immunotherapy combo comes up short in melanoma trial

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out...

Regeneron, Telix Launch Up-to-$4.3B Cancer-Focused Radiopharma Drug, Diagnostic Collaboration

The companies have agreed to partner on next-generation radiopharmaceutical therapies aimed at up-to-eight solid tumor targets from Regeneron’s portfolio of antibodies, generated f...

FDA approves Regeneron’s hearing loss gene therapy

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to...

Apogee Therapeutics: Targeting Atopic Dermatitis

Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy

GEN's senior business editor, Alex Philippidis, compiles the latest cell-and-gene therapy business news and trends. The post Gene Therapy Briefs: Regeneron Wins FDA Approval for Fi...

Regenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapy

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a win for a biotech that has struggled in recent months und...

Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality shine through his mute world.

Regeneron shares fall 12% on disappointing melanoma trial data

Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial

A phase 3 trial of Regeneron’s LAG-3 inhibitor has missed its primary endpoint, leaving the biopharma reeling from the second failure of a key late-stage program in the past year.

White House to Announce Drug Pricing Deal with Regeneron

Regeneron becomes the last of 17 major drugmakers to sign on, but the secret terms and cash-only focus leave millions of insured Americans wondering what — if anything — changes fo...